Senthilnath Lakshmanachetty

City College of San Francisco — United States

Medicine · Health Sciences

8h-index238citations106works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(45), Microtubule and mitosis dynamics(19), RNA regulation and disease(17), CAR-T cell therapy research(15), Nuclear Receptors and Signaling(13)

Publications106 total

TMIC-110. Role of LRRC25 in local and systemic immunosuppression and its reversal
Neuro-Oncology·2025Open Access
CNSC-15. TARGETING GLIOMA-NEURONAL CIRCUIT REMODELING TO OVERCOME IMMUNOSUPPRESSION: FUNCTIONAL AND THERAPEUTIC INSIGHTS
Neuro-Oncology·2025Open Access
EXTH-52. Spatially Resolved Antigenic Landscapes In Low-grade Glioma Reveal Targets For Personalized Immunotherapy
Neuro-Oncology·2025Open Access
IMMU-14. Focused ultrasound–mediated blood-brain barrier disruption, combined with antigen-presenting cell activation, promotes CNS antigen-specific T cell immunity and bypasses immunotherapy resistance mechanism in malignant brain tumors
Neuro-Oncology·2025Open Access
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas
Journal for ImmunoTherapy of Cancer·2025Open Access
Supplementary Figure S9 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Figure S10 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Figure S3 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Figure S1 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Table S6 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Figure S2 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary FIgure S4 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Table S5 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Figure S5 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Table S2 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Key Resource Table from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Table S1 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Table S3 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Figure S8 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
Supplementary Figure S7 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
2025Open Access
page 1 of 6Next →

Frequent Co-authors

Ilango Balakrishnan(24), Sujatha Venkataraman(24), Rajeev Vibhakar(24), Angela Pierce(23), Nathan Dahl(21), Hideho Okada(19), Akane Yamamichi(16), Etienne Danis(15), Andrew M. Donson(15), Siddhartha S. Mitra(14), Takahide Nejo(14), Payal Watchmaker(14), Krishna Madhavan(14), Dong Wang(13), John DeSisto(13), Nicholas K. Foreman(12), Bridget Sanford(12), Marco Gallus(11), Irina Alimova(11), Natalie J. Serkova(11)